The effect of antidepressant treatment on HIV and depression outcomes: Results from a randomized trial

Brian W. Pence, Bradley N. Gaynes, Julie L. Adams, Nathan M. Thielman, Amy D. Heine, Michael J. Mugavero, Teena McGuinness, James L. Raper, James H. Willig, Kristen G. Shirey, Michelle Ogle, Elizabeth L. Turner, E. Byrd Quinlivan

Research output: Contribution to journalArticle

Abstract

Background: Depression is a major barrier to HIV treatment outcomes. Objective: To test whether antidepressant management decision support integrated into HIV care improves antiretroviral adherence and depression morbidity. Design: Pseudo-cluster randomized trial. Setting: Four US infectious diseases clinics. Participants: HIV-infected adults with major depressive disorder. Intervention: Measurement-based care (MBC)-depression care managers used systematic metrics to give HIV primary-care clinicians standardized antidepressant treatment recommendations. Measurements: Primary-antiretroviral medication adherence (monthly unannounced telephone-based pill counts for 12 months). Primary time-point-6 months. Secondary-depressive severity, depression remission, depression-free days, measured quarterly for 12 months. Results: From 2010 to 2013, 149 participants were randomized to intervention and 155 to usual care. Participants were mostly men, Black, non-Hispanic, unemployed, and virally suppressed with high baseline self-reported antiretroviral adherence and depressive severity. Over follow-up, no differences between arms in antiretroviral adherence or other HIV outcomes were apparent. At 6 months, depressive severity was lower among intervention participants than usual care [mean difference-3.7, 95% confidence interval (CI)-5.6,-1.7], probability of depression remission was higher [risk difference 13%, 95% CI 1%, 25%), and suicidal ideation was lower (risk difference-18%, 95% CI-30%,-6%). By 12 months, the arms had comparable mental health outcomes. Intervention arm participants experienced an average of 29 (95% CI: 1-57) more depression-free days over 12 months. Conclusion: In the largest trial of its kind among HIV-infected adults, MBC did not improve HIV outcomes, possibly because of high baseline adherence, but achieved clinically significant depression improvements and increased depression-free days. MBC may be an effective, resource-efficient approach to reducing depression morbidity among HIV patients.

Original languageEnglish (US)
Pages (from-to)1975-1986
Number of pages12
JournalAIDS
Volume29
Issue number15
DOIs
StatePublished - Sep 24 2015
Externally publishedYes

Keywords

  • antiretroviral adherence
  • depression
  • HIV
  • measurement-based care depression treatment
  • pseudo-cluster randomization
  • randomized trial

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Pence, B. W., Gaynes, B. N., Adams, J. L., Thielman, N. M., Heine, A. D., Mugavero, M. J., ... Quinlivan, E. B. (2015). The effect of antidepressant treatment on HIV and depression outcomes: Results from a randomized trial. AIDS, 29(15), 1975-1986. https://doi.org/10.1097/QAD.0000000000000797

The effect of antidepressant treatment on HIV and depression outcomes : Results from a randomized trial. / Pence, Brian W.; Gaynes, Bradley N.; Adams, Julie L.; Thielman, Nathan M.; Heine, Amy D.; Mugavero, Michael J.; McGuinness, Teena; Raper, James L.; Willig, James H.; Shirey, Kristen G.; Ogle, Michelle; Turner, Elizabeth L.; Quinlivan, E. Byrd.

In: AIDS, Vol. 29, No. 15, 24.09.2015, p. 1975-1986.

Research output: Contribution to journalArticle

Pence, BW, Gaynes, BN, Adams, JL, Thielman, NM, Heine, AD, Mugavero, MJ, McGuinness, T, Raper, JL, Willig, JH, Shirey, KG, Ogle, M, Turner, EL & Quinlivan, EB 2015, 'The effect of antidepressant treatment on HIV and depression outcomes: Results from a randomized trial', AIDS, vol. 29, no. 15, pp. 1975-1986. https://doi.org/10.1097/QAD.0000000000000797
Pence BW, Gaynes BN, Adams JL, Thielman NM, Heine AD, Mugavero MJ et al. The effect of antidepressant treatment on HIV and depression outcomes: Results from a randomized trial. AIDS. 2015 Sep 24;29(15):1975-1986. https://doi.org/10.1097/QAD.0000000000000797
Pence, Brian W. ; Gaynes, Bradley N. ; Adams, Julie L. ; Thielman, Nathan M. ; Heine, Amy D. ; Mugavero, Michael J. ; McGuinness, Teena ; Raper, James L. ; Willig, James H. ; Shirey, Kristen G. ; Ogle, Michelle ; Turner, Elizabeth L. ; Quinlivan, E. Byrd. / The effect of antidepressant treatment on HIV and depression outcomes : Results from a randomized trial. In: AIDS. 2015 ; Vol. 29, No. 15. pp. 1975-1986.
@article{41d49d6b21314797a88b6cb9111e4b3a,
title = "The effect of antidepressant treatment on HIV and depression outcomes: Results from a randomized trial",
abstract = "Background: Depression is a major barrier to HIV treatment outcomes. Objective: To test whether antidepressant management decision support integrated into HIV care improves antiretroviral adherence and depression morbidity. Design: Pseudo-cluster randomized trial. Setting: Four US infectious diseases clinics. Participants: HIV-infected adults with major depressive disorder. Intervention: Measurement-based care (MBC)-depression care managers used systematic metrics to give HIV primary-care clinicians standardized antidepressant treatment recommendations. Measurements: Primary-antiretroviral medication adherence (monthly unannounced telephone-based pill counts for 12 months). Primary time-point-6 months. Secondary-depressive severity, depression remission, depression-free days, measured quarterly for 12 months. Results: From 2010 to 2013, 149 participants were randomized to intervention and 155 to usual care. Participants were mostly men, Black, non-Hispanic, unemployed, and virally suppressed with high baseline self-reported antiretroviral adherence and depressive severity. Over follow-up, no differences between arms in antiretroviral adherence or other HIV outcomes were apparent. At 6 months, depressive severity was lower among intervention participants than usual care [mean difference-3.7, 95{\%} confidence interval (CI)-5.6,-1.7], probability of depression remission was higher [risk difference 13{\%}, 95{\%} CI 1{\%}, 25{\%}), and suicidal ideation was lower (risk difference-18{\%}, 95{\%} CI-30{\%},-6{\%}). By 12 months, the arms had comparable mental health outcomes. Intervention arm participants experienced an average of 29 (95{\%} CI: 1-57) more depression-free days over 12 months. Conclusion: In the largest trial of its kind among HIV-infected adults, MBC did not improve HIV outcomes, possibly because of high baseline adherence, but achieved clinically significant depression improvements and increased depression-free days. MBC may be an effective, resource-efficient approach to reducing depression morbidity among HIV patients.",
keywords = "antiretroviral adherence, depression, HIV, measurement-based care depression treatment, pseudo-cluster randomization, randomized trial",
author = "Pence, {Brian W.} and Gaynes, {Bradley N.} and Adams, {Julie L.} and Thielman, {Nathan M.} and Heine, {Amy D.} and Mugavero, {Michael J.} and Teena McGuinness and Raper, {James L.} and Willig, {James H.} and Shirey, {Kristen G.} and Michelle Ogle and Turner, {Elizabeth L.} and Quinlivan, {E. Byrd}",
year = "2015",
month = "9",
day = "24",
doi = "10.1097/QAD.0000000000000797",
language = "English (US)",
volume = "29",
pages = "1975--1986",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "15",

}

TY - JOUR

T1 - The effect of antidepressant treatment on HIV and depression outcomes

T2 - Results from a randomized trial

AU - Pence, Brian W.

AU - Gaynes, Bradley N.

AU - Adams, Julie L.

AU - Thielman, Nathan M.

AU - Heine, Amy D.

AU - Mugavero, Michael J.

AU - McGuinness, Teena

AU - Raper, James L.

AU - Willig, James H.

AU - Shirey, Kristen G.

AU - Ogle, Michelle

AU - Turner, Elizabeth L.

AU - Quinlivan, E. Byrd

PY - 2015/9/24

Y1 - 2015/9/24

N2 - Background: Depression is a major barrier to HIV treatment outcomes. Objective: To test whether antidepressant management decision support integrated into HIV care improves antiretroviral adherence and depression morbidity. Design: Pseudo-cluster randomized trial. Setting: Four US infectious diseases clinics. Participants: HIV-infected adults with major depressive disorder. Intervention: Measurement-based care (MBC)-depression care managers used systematic metrics to give HIV primary-care clinicians standardized antidepressant treatment recommendations. Measurements: Primary-antiretroviral medication adherence (monthly unannounced telephone-based pill counts for 12 months). Primary time-point-6 months. Secondary-depressive severity, depression remission, depression-free days, measured quarterly for 12 months. Results: From 2010 to 2013, 149 participants were randomized to intervention and 155 to usual care. Participants were mostly men, Black, non-Hispanic, unemployed, and virally suppressed with high baseline self-reported antiretroviral adherence and depressive severity. Over follow-up, no differences between arms in antiretroviral adherence or other HIV outcomes were apparent. At 6 months, depressive severity was lower among intervention participants than usual care [mean difference-3.7, 95% confidence interval (CI)-5.6,-1.7], probability of depression remission was higher [risk difference 13%, 95% CI 1%, 25%), and suicidal ideation was lower (risk difference-18%, 95% CI-30%,-6%). By 12 months, the arms had comparable mental health outcomes. Intervention arm participants experienced an average of 29 (95% CI: 1-57) more depression-free days over 12 months. Conclusion: In the largest trial of its kind among HIV-infected adults, MBC did not improve HIV outcomes, possibly because of high baseline adherence, but achieved clinically significant depression improvements and increased depression-free days. MBC may be an effective, resource-efficient approach to reducing depression morbidity among HIV patients.

AB - Background: Depression is a major barrier to HIV treatment outcomes. Objective: To test whether antidepressant management decision support integrated into HIV care improves antiretroviral adherence and depression morbidity. Design: Pseudo-cluster randomized trial. Setting: Four US infectious diseases clinics. Participants: HIV-infected adults with major depressive disorder. Intervention: Measurement-based care (MBC)-depression care managers used systematic metrics to give HIV primary-care clinicians standardized antidepressant treatment recommendations. Measurements: Primary-antiretroviral medication adherence (monthly unannounced telephone-based pill counts for 12 months). Primary time-point-6 months. Secondary-depressive severity, depression remission, depression-free days, measured quarterly for 12 months. Results: From 2010 to 2013, 149 participants were randomized to intervention and 155 to usual care. Participants were mostly men, Black, non-Hispanic, unemployed, and virally suppressed with high baseline self-reported antiretroviral adherence and depressive severity. Over follow-up, no differences between arms in antiretroviral adherence or other HIV outcomes were apparent. At 6 months, depressive severity was lower among intervention participants than usual care [mean difference-3.7, 95% confidence interval (CI)-5.6,-1.7], probability of depression remission was higher [risk difference 13%, 95% CI 1%, 25%), and suicidal ideation was lower (risk difference-18%, 95% CI-30%,-6%). By 12 months, the arms had comparable mental health outcomes. Intervention arm participants experienced an average of 29 (95% CI: 1-57) more depression-free days over 12 months. Conclusion: In the largest trial of its kind among HIV-infected adults, MBC did not improve HIV outcomes, possibly because of high baseline adherence, but achieved clinically significant depression improvements and increased depression-free days. MBC may be an effective, resource-efficient approach to reducing depression morbidity among HIV patients.

KW - antiretroviral adherence

KW - depression

KW - HIV

KW - measurement-based care depression treatment

KW - pseudo-cluster randomization

KW - randomized trial

UR - http://www.scopus.com/inward/record.url?scp=84965025725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965025725&partnerID=8YFLogxK

U2 - 10.1097/QAD.0000000000000797

DO - 10.1097/QAD.0000000000000797

M3 - Article

C2 - 26134881

AN - SCOPUS:84965025725

VL - 29

SP - 1975

EP - 1986

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 15

ER -